Novartis ends Fabhalta study in lupus nephritis; Fate doses first patient in registrational trial

Novartis ended its Fabhalta study in lupus nephritis. Fate Therapeutics dosed the first patient in a potentially registrational trial, and Adicet Bio starts pivotal preparation this quarter, while Aurinia holds the commercial side.

Detected & updated continuously · Source: Nebula